Skip to content

Primary vs secondary hypogonadism: hypogonadotropic hypogonadism, LH and FSH, and treatment

Vladimir Kotlov, MD avatar
Vladimir Kotlov, MD: Founder & CEO at Veedma
Nov 16, 2026 · 17 min read

Listen to this article as a podcast episode

May 07, 2026 · 18:13

Primary hypogonadism means low testosterone with high LH and FSH, while secondary hypogonadism means low testosterone with low or inappropriately normal LH and FSH. That distinction determines whether a man is more likely to need testosterone replacement or may be able to restore his own production with Enclomiphene. A low number alone cannot make that call, and treating every man the same can permanently compromise fertility.

Find the cause before treating it

Choose a lab panel and get a clinical review with clear next steps.

Order your lab panel

Key takeaways

  • Primary hypogonadism, also called hypergonadotropic hypogonadism, is defined by low testosterone with elevated LH and FSH. The pituitary is signaling strongly, but the testes are not responding.[1] [2]
  • Secondary hypogonadism, also called hypogonadotropic hypogonadism, is defined by low testosterone with low or inappropriately normal LH and FSH.[1] [2] In a 2014 randomized trial in men with secondary hypogonadism, Enclomiphene raised testosterone while sperm counts were conserved.[3] That result shows the testes can still respond to stimulation in this type.
  • According to the Endocrine Society guideline, diagnosis requires symptoms plus consistently low fasting morning testosterone confirmed on a repeat test.[1] When SHBG is altered, free testosterone should be measured by equilibrium dialysis or estimated with an accurate formula. LH and FSH then identify the type.[1]
  • Klinefelter syndrome, the most common sex chromosome disorder in men, affects about 1 in 660 men and causes primary hypogonadism.[4] Only about 25% of cases are ever diagnosed.[4]
  • Functional hypogonadism, driven by obesity, diabetes, medications, or other reversible conditions, is the most common pattern in practice. A 2013 meta-analysis found that weight loss raises testosterone in obese men, with larger gains after bariatric surgery than after a low calorie diet.[5]
  • Compensated hypogonadism means testosterone is still in range but LH is elevated. The European Male Ageing Study described it as a distinct state associated with aging rather than established testosterone deficiency.[2]

How to classify the type of low testosterone

Primary vs secondary hypogonadism is defined by reading testosterone together with LH and FSH, not by testosterone alone.[1] [2]

Male hypogonadism is a clinical syndrome that requires both persistent symptoms and biochemical evidence of testosterone deficiency.[1] A low number alone is not enough, and symptoms alone are not enough either. For the full syndrome based definition, see What is low testosterone? The clinical definition most men and many doctors get wrong.

Gonadotropins are pituitary hormones that stimulate the testes. LH mainly drives testosterone production, and FSH mainly supports spermatogenesis. The Endocrine Society guideline recommends further evaluation to find the cause in every man diagnosed with testosterone deficiency.[1] Measuring LH and FSH is the step that separates testicular failure from hypothalamic or pituitary suppression.

Hypergonadotropic means LH and FSH are elevated. Hypogonadotropic means LH and FSH are low or inappropriately normal. The HPG axis is the brain to testes signaling loop that controls testosterone production. For a deeper explanation of that signaling pathway, see How the HPG axis works: the brain testes connection explained.

Classification starts with a morning blood draw. The Endocrine Society recommends measuring fasting morning total testosterone with an accurate, reliable assay and confirming a low result with a repeat measurement.[1] When total testosterone is near the lower limit of normal or a condition alters SHBG, it recommends obtaining free testosterone by equilibrium dialysis or an accurate formula.[1] Free testosterone matters because elevated SHBG can hide clinically important deficiency when total testosterone looks acceptable. LH and FSH need to be measured with testosterone, because without them the type cannot be classified. For the full panel and workflow, see The complete low testosterone testing guide: what to order, when to test, and how to read results.

TypeTestosterone patternLH and FSH patternWhere the problem startsTreatment direction
Primary hypogonadismLowHighTestesTestosterone replacement is usually required
Secondary hypogonadismLowLow or inappropriately normalHypothalamus or pituitaryTreat the cause; stimulation therapy may restore production when the axis is intact
Functional hypogonadismLowUsually low or normalReversible suppression of an intact axisAddress causes; stimulation of natural production can be considered
Androgen resistance or decreased bioactivityNormal or borderlineVariableHormone action, conversion, or bioavailabilityTreat the mechanism, not the number alone
Compensated hypogonadismNormalLH highEarly strain on the axisMonitor closely

This is why two men with the same total testosterone, such as 200 ng/dL, may need opposite treatments. One has primary hypogonadism and needs replacement because the testes cannot respond.[1] The other has secondary or functional hypogonadism. He may recover his own production with stimulation therapy such as Enclomiphene, which in early trials raised testosterone while maintaining testicular volume and, potentially, spermatogenesis.[6]

Primary hypogonadism means testicular failure

Primary hypogonadism means the testes cannot produce enough testosterone despite strong pituitary stimulation.[1] [2]

Primary hypogonadism is the classic hypergonadotropic pattern: low testosterone with elevated LH and FSH. The European Male Ageing Study included 3,369 men aged 40 to 79.[2] Primary hypogonadism was found in 2.0% of them and was linked mainly to older age, while secondary hypogonadism was linked mainly to obesity.[2]

Congenital causes of primary hypogonadism

Congenital means present from birth. The most common genetic cause is Klinefelter syndrome, usually 47,XXY. A 2013 clinical review in the Journal of Clinical Endocrinology and Metabolism reports that Klinefelter syndrome affects about 1 in 660 men.[4] Its key findings are small testes and hypergonadotropic hypogonadism, and only about 25% of cases are diagnosed, at an average age in the mid 30s.[4]

Other congenital causes include cryptorchidism, bilateral anorchia, and myotonic dystrophy.[1]

Acquired causes of primary hypogonadism

Acquired means the damage happened after birth. Important causes include chemotherapy, testicular irradiation, surgical removal of the testes, testicular trauma, and orchitis, including mumps orchitis.[1] Testicular torsion can cause similar damage.

In each case, Leydig cells, the testicular cells that make testosterone, are damaged or absent, so raising pituitary output further does not restore production.

Why treatment is different in primary hypogonadism

Testosterone replacement is the standard treatment for symptomatic testosterone deficiency in primary hypogonadism.[1]

Stimulation therapies work only if the testes can still respond, and in primary disease they usually cannot. Exogenous testosterone can improve symptoms and correct the deficiency. However, it suppresses LH and FSH further and can impair any remaining spermatogenesis. The Endocrine Society recommends against starting testosterone in men planning fertility in the near term, so fertility counseling belongs before treatment starts.[1]

Secondary hypogonadism means central signal failure

Secondary hypogonadism means the testes may still work, but the hypothalamus or pituitary is not sending enough signal.[1] [2]

Secondary hypogonadism is also called hypogonadotropic hypogonadism. The laboratory pattern is low testosterone with low or inappropriately normal LH and FSH. The key phrase is “inappropriately normal.” If testosterone is truly low, LH and FSH should rise. When they do not, the central signal is failing.

Common causes of secondary hypogonadism

Causes of secondary hypogonadism fall into a few groups.[1]

  • Drug induced causes, including opiates, exogenous testosterone or anabolic steroids, GnRH agonists or antagonists, glucocorticoids, and estrogens
  • Localized causes, including pituitary tumors, traumatic brain injury, pituitary surgery or irradiation, and hyperprolactinemia
  • Systemic causes, including type 2 diabetes, metabolic syndrome, obesity, chronic organ failure, eating disorders, endurance overtraining, and acute illness

These categories matter because some are reversible, some are treatable at the source, and some require long term hormonal management.

Why Enclomiphene fits secondary hypogonadism

Stimulation can work in secondary hypogonadism because the testes can still respond to LH and FSH. A 2009 review of early clinical trials reported that Enclomiphene restored testosterone production in men with secondary hypogonadism.[6] Its short term safety was similar to that of testosterone gel and placebo.[6]

Enclomiphene is an estrogen receptor antagonist. By blocking estrogen feedback at the hypothalamus, it increases GnRH release, raises LH and FSH output from the pituitary, and prompts the testes to produce testosterone.[6] A 2014 randomized phase II trial in Fertility and Sterility studied men with secondary hypogonadism.[3] Enclomiphene raised testosterone and LH to levels similar to those achieved with topical testosterone gel, while also raising FSH and conserving sperm counts.[3]

A man may be a candidate for stimulation therapy if he has persistent symptoms, confirmed low testosterone, low or normal LH, and no structural cause that needs its own treatment. When fertility is the immediate goal, hCG, alone or with FSH, is the established way to induce sperm production in secondary hypogonadism.[1] For men who do not need immediate fertility treatment, Enclomiphene is an oral alternative that also keeps the testes working.

What is congenital hypogonadotropic hypogonadism?

Congenital hypogonadotropic hypogonadism is a rare form of secondary hypogonadism that is present from birth. It is caused by deficient production, secretion, or action of gonadotropin releasing hormone (GnRH).[7]

GnRH is the master hormone of the hypothalamic pituitary gonadal axis. Without it, the pituitary gland does not release enough LH and FSH, so the testes are never told to make testosterone or sperm. A 2015 European consensus statement in Nature Reviews Endocrinology describes the typical presentation as absent puberty and infertility.[7] More than 25 causal genes have been identified.[7]

Kallmann syndrome and the sense of smell

When congenital hypogonadotropic hypogonadism comes with a missing or reduced sense of smell (anosmia or hyposmia), it is called Kallmann syndrome. The same consensus statement reports this in about 50% of patients.[7] It happens because the neurons that make GnRH fail to migrate fully during embryonic development.[7]

How it differs from the adult types of hypogonadism

Congenital hypogonadotropic hypogonadism usually shows up in the teenage years, and it can be hard to tell apart from puberty that is simply late. Low testosterone that begins in adulthood after a normal puberty points instead to the acquired or functional causes above. Most men with the congenital form need lifelong treatment, and fertility can usually be induced with specialized regimens. About 10% to 20% of patients recover reproductive function on their own.[7]

Low testosterone with low or normal LH and FSH does not by itself show whether the cause is congenital, structural, or functional. Puberty history, medications, body weight, and further testing help separate them.

Functional hypogonadism is the most common reversible pattern

Functional hypogonadism is low testosterone caused by reversible suppression of an otherwise intact HPG axis.[1] [5]

Functional hypogonadism is diagnosed when no organic damage is found in the hypothalamus, pituitary, or testes, and low testosterone is driven instead by comorbidities and reversible stressors. In the European Male Ageing Study, secondary hypogonadism was about six times as common as primary (11.8% vs 2.0%).[2] A body mass index of 30 or higher was strongly associated with it.[2] Weight loss lowers estradiol and raises LH and FSH, which indicates that excess fat mass suppresses the axis without destroying it.[5]

What drives functional hypogonadism

The main drivers are obesity, metabolic syndrome, type 2 diabetes, medications, chronic organ failure, overtraining, disordered eating, and acute illness. This is still a form of secondary hypogonadism by location, but it deserves separate attention because the axis is suppressed, not structurally broken.[1]

Treating the cause and the suppressed axis

Treatment of functional hypogonadism starts with the underlying cause: weight loss, medication changes, and better control of diabetes and other conditions.

A 2013 systematic review and meta-analysis of 24 studies in the European Journal of Endocrinology looked at weight loss and testosterone.[5] A low calorie diet raised total testosterone by about 2.9 nmol/L and bariatric surgery by about 8.7 nmol/L, with larger gains in men who lost more weight.[5] Outside of trials, the gain from lifestyle change alone is often smaller, about 1 to 2 nmol/L. Durability is also a problem: an estimated 60% to 86% of lost weight is regained within 3 years. Because the axis is intact, stimulation therapy such as Enclomiphene can raise testosterone while the underlying drivers are addressed. The 2009 review noted its potential in secondary hypogonadism associated with obesity and metabolic syndrome and called for placebo controlled trials in these groups.[6]

Misclassification has real consequences. If a reversible, intact axis is treated as if it were irreversible testicular failure, a man may be placed on lifelong testosterone therapy unnecessarily and lose fertility in the process.

Androgen resistance and decreased bioactivity form a third category

Androgen resistance can produce androgen deficiency even when total testosterone does not look low.[8]

The problem is not always how much testosterone is present. Sometimes it is how well tissues can use it. The androgen receptor is the cellular docking site for testosterone and dihydrotestosterone. Five alpha reductase is the enzyme that converts testosterone to dihydrotestosterone in target tissues.

Congenital forms of androgen resistance

A 1995 Endocrine Reviews article by Quigley and colleagues describes congenital androgen receptor defects ranging from complete androgen insensitivity to milder undervirilization syndromes.[8] Other congenital causes of reduced androgen action include 5 alpha reductase deficiency, Kennedy disease, and variations in androgen receptor CAG repeat length that can alter tissue responsiveness.

Acquired forms of decreased androgen bioactivity

Acquired forms include finasteride and dutasteride, which block 5 alpha reductase, and spironolactone and other antiandrogens, which block the receptor. Conditions that raise SHBG reduce the fraction of testosterone that is freely available to tissues. For that reason the Endocrine Society recommends measuring free testosterone in men with conditions that alter SHBG.[1]

A man can have a total testosterone result that looks “normal” and still have low androgen bioactivity because too little hormone is free to act. The evidence for some acquired bioactivity states is less standardized than for classic primary and secondary hypogonadism. Androgen action therefore has to be interpreted in clinical context rather than from one total testosterone number.

Compensated hypogonadism is a warning pattern

Compensated hypogonadism means testosterone remains normal while LH is elevated.[2]

The pituitary is working harder than usual to keep testosterone in range. The European Male Ageing Study found this pattern in 9.5% of men aged 40 to 79, and it was more common with older age.[2] Men with it were more likely to report physical symptoms, whereas sexual symptoms were more typical of primary and secondary hypogonadism. The authors described it as a distinct clinical state associated with aging.[2]

The clinical significance is still uncertain. It may represent early or evolving gonadal failure, or a state in which the axis is under strain but not yet failing. It does not represent confirmed testosterone deficiency by itself, because normal testosterone means the biochemical criterion for overt hypogonadism has not been met.

Compensated hypogonadism is best viewed as a sign worth monitoring, especially if symptoms are emerging or risk factors for primary testicular failure are present.

Age of onset changes how hypogonadism looks

The age at which hypogonadism begins shapes how strongly it affects development and symptoms.

The same endocrine problem can look completely different depending on whether it begins in fetal life, around puberty, or in adult life. Earlier onset forms alter development itself. In adults the picture is subtler. A 2005 Endocrine Reviews article by Kaufman and Vermeulen reports that more than 20% of healthy men over 60 have testosterone below the range for young men.[9] Because aging itself resembles hypogonadism, borderline deficiency cannot be reliably diagnosed in older men.[9]

Fetal onset

Fetal onset can range from an externally female phenotype to milder virilization defects. The outcome depends on when the androgen signal fails and whether the problem lies in testosterone production, conversion to dihydrotestosterone, or androgen receptor function.[8]

Pre and peri pubertal onset

Pre pubertal and peri pubertal onset can present with delayed or absent puberty, poor virilization, small testes, and eunuchoid body proportions. Congenital hypogonadotropic hypogonadism is the main example, and the European consensus statement notes it can be challenging to distinguish from constitutional delay of puberty.[7]

Post pubertal and adult onset

Post pubertal or adult onset hypogonadism, including late onset hypogonadism, is usually milder in appearance and often mistaken for stress, weight gain, or aging. Sexual symptoms, reduced physical performance, fat gain, and mood changes may accumulate slowly rather than appearing abruptly. For a fuller symptom framework, see How low testosterone symptoms show up differently at every age.

This age effect is one more reason that classification must be clinical, not purely numeric. The same testosterone value can mean very different things in three different men:

  • A man who never completed puberty
  • A young man with secondary suppression from drugs or obesity
  • An older man with emerging testicular failure

Myth vs fact

Myth: A low testosterone number alone diagnoses hypogonadism

Fact: Male hypogonadism requires persistent symptoms plus consistently low testosterone. Once deficiency is confirmed, LH and FSH show whether the problem is primary or secondary.[1] [2]

Myth: All types of low testosterone are treated the same way

Fact: Primary hypogonadism usually requires testosterone replacement. Secondary hypogonadism, including the functional form, may respond to treating the cause or to stimulation therapy such as Enclomiphene, because the testes can still respond.[1] [6]

Myth: Normal LH rules out a brain signal problem

Fact: In a man with low testosterone, a “normal” LH can be abnormal because it is inappropriately low for the degree of deficiency. That pattern supports secondary hypogonadism.[1] [2]

Myth: TRT is fertility neutral

Fact: Exogenous testosterone suppresses LH, FSH, and sperm production, and the Endocrine Society recommends against starting it in men planning fertility in the near term.[1] In a randomized trial in men with secondary hypogonadism, Enclomiphene raised testosterone to levels similar to topical testosterone while conserving sperm counts.[3]

Myth: Normal total testosterone means androgen action is normal

Fact: Androgen receptor defects can cause androgen deficiency despite normal testosterone levels.[8] Five alpha reductase defects, receptor blocking drugs, and high SHBG can also reduce androgen action when total testosterone is not low.

Bottom line

Where low testosterone starts determines whether treatment should replace testosterone or stimulate natural production. Primary hypogonadism points to testicular failure and usually requires replacement. Secondary and functional hypogonadism can often be approached with fertility preserving stimulation, such as Enclomiphene, when the axis is intact. For the full diagnostic and treatment roadmap, see the Low Testosterone hub.

Veedma offers testing that includes total and free testosterone measured by LC-MS/MS with LH and FSH, or a review of labs you already have. Licensed providers interpret the results and, when appropriate, prescribe Enclomiphene or the Enclomiphene plus Tadalafil tablet. Enclomiphene is not an FDA-approved drug; it is prescribed after a provider confirms the diagnosis and is compounded by a licensed U.S. pharmacy.

References

  1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103:1715-1744. PMID: 29562364
  2. Tajar A, Forti G, O’Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010;95:1810-8. PMID: 20173018
  3. Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102:720-7. PMID: 25044085
  4. Groth KA, Skakkebæk A, Høst C, et al. Clinical review: Klinefelter syndrome–a clinical update. J Clin Endocrinol Metab. 2013;98:20-30. PMID: 23118429
  5. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168:829-43. PMID: 23482592
  6. Hill S, Arutchelvam V, Quinton R. Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men. IDrugs. 2009;12:109-19. PMID: 19204885
  7. Boehm U, Bouloux PM, Dattani MT, et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism–pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2015;11:547-64. PMID: 26194704
  8. Quigley CA, De Bellis A, Marschke KB, et al. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev. 1995;16:271-321. PMID: 7671849
  9. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;26:833-76. PMID: 15901667

Start with a lab panel

Get a clinical review of your results and health history, with an explanation of the decision and next steps in your patient chat. If you are eligible and want treatment, choose a plan and save a card to book a video visit at no extra visit fee. Treatment billing starts only if prescribed.

Order your lab panel

Prefer short video breakdowns? Follow @veedma.men on TikTok for quick, study-backed men's hormone explainers.

Vladimir Kotlov, MD

Vladimir Kotlov, MD: Founder & CEO at Veedma

Vladimir Kotlov, MD is the founder of Veedma. A urologist by training, he led a urology department at a fertility and reproductive clinic where he managed a team of 30+ clinicians and improved IVF outcomes by 24%. He then moved to Silicon Valley and spent five years advising healthtech companies before founding Veedma to help men access evidence-based hormone optimization and fertility care.